2024
Changes in Risk Tolerance for Ovarian Cancer Prevention Strategies during the COVID-19 Pandemic: Results of a Discrete Choice Experiment
Egleston B, Daly M, Lew K, Bealin L, Husband A, Stopfer J, Przybysz P, Tchuvatkina O, Wong Y, Garber J, Rebbeck T. Changes in Risk Tolerance for Ovarian Cancer Prevention Strategies during the COVID-19 Pandemic: Results of a Discrete Choice Experiment. Medical Decision Making 2024, 45: 168-176. PMID: 39722532, PMCID: PMC11881031, DOI: 10.1177/0272989x241302829.Peer-Reviewed Original ResearchConceptsHigher ovarian cancer riskRisk of ovarian cancerRisk-reducing surgeryOvarian cancer riskCancer prevention strategiesCancer riskPrevention strategiesOvarian cancerOvarian cancer prevention strategiesElevated risk of breastRisk of breastCOVID-19 pandemicPrevention scenariosInfluence patients' decisionsRisk-reducing strategiesMedical decision makingAge of menopauseDiscrete choice experimentPatient's decisionElevated riskGenetic testingCOVID-19Menopausal symptomsMedical CenterHeart disease
2006
BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50
Haile R, Thomas D, McGuire V, Felberg A, John E, Milne R, Hopper J, Jenkins M, Levine A, Daly M, Buys S, Senie R, Andrulis I, Knight J, Godwin A, Southey M, McCredie M, Giles G, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike M, Whittemore A, Investigators K. BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50. Cancer Epidemiology Biomarkers & Prevention 2006, 15: 1863-1870. PMID: 17021353, DOI: 10.1158/1055-9965.epi-06-0258.Peer-Reviewed Original ResearchMeSH KeywordsAdultAustraliaBreast NeoplasmsCanadaCarcinoma in SituCarcinoma, Ductal, BreastCase-Control StudiesContraceptives, OralFemaleGenes, BRCA1Genes, BRCA2Genetic Predisposition to DiseaseHeterozygoteHumansLogistic ModelsMiddle AgedMutationReceptors, EstrogenReceptors, ProgesteroneRisk FactorsSurveys and QuestionnairesTime FactorsUnited StatesConceptsRisk of breast cancerBRCA2 mutation carriersOral contraceptive useMutation carriersAssociated with breast cancer riskIncreased risk of breast cancerBreast cancerOral contraceptivesContraceptive useBreast cancer riskUnconditional logistic regressionDuration of oral contraceptive useBRCA1 mutation carriersDuration of useCase-control analysisEffects of oral contraceptivesCancer riskFamily historyModify practicesElevated riskLogistic regressionIncreased riskBRCA2Family relationshipsBRCA1
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply